Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-26-056213
Filing Date
2026-08-12
Accepted
2026-08-12 16:17:18
Documents
77
Period of Report
2026-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q allo-20260630.htm   iXBRL 10-Q 1533753
2 EX-10.1 allo-20260630xex101.htm EX-10.1 26724
3 EX-10.2 allo-20260630xex102.htm EX-10.2 308110
4 EX-10.4 allo-20260630xex104.htm EX-10.4 266489
5 EX-10.5 allo-20260630xex105.htm EX-10.5 14370
6 EX-31.1 allo-20260630xex311.htm EX-31.1 9686
7 EX-31.2 allo-20260630xex312.htm EX-31.2 9624
8 EX-32.1 allo-20260630xex321.htm EX-32.1 7037
14 allogenelogoa.jpg GRAPHIC 14655
  Complete submission text file 0001628280-26-056213.txt   8367412

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT allo-20260630.xsd EX-101.SCH 63471
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT allo-20260630_cal.xml EX-101.CAL 58050
11 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT allo-20260630_def.xml EX-101.DEF 379337
12 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT allo-20260630_lab.xml EX-101.LAB 703609
13 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT allo-20260630_pre.xml EX-101.PRE 500822
81 EXTRACTED XBRL INSTANCE DOCUMENT allo-20260630_htm.xml XML 841430
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38693 | Film No.: 261267747
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)